Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

May 2023

Fort Lee, N.J., May 17, 2023 – Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced it submitted a

Read more